Lineage Cell Therapeutics
LCTX
118 hedge funds and large institutions have $85.9M invested in Lineage Cell Therapeutics in 2019 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 44 increasing their positions, 20 reducing their positions, and 17 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 20
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
65% more capital invested
Capital invested by funds: $52.1M → $85.9M (+$33.8M)
18% more call options, than puts
Call options by funds: $98K | Put options by funds: $83K
12% more funds holding
Funds holding: 105 → 118 (+13)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.08% less ownership
Funds ownership: 44.95% → 43.87% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$4.67M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.97M |
| 3 |
BlackRock
New York
|
+$1.29M |
| 4 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$510K |
| 5 |
PCM
Price Capital Management
Lafayette,
Louisiana
|
+$408K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IndexIQ Advisors
New York
|
-$715K |
| 2 |
State Street
Boston,
Massachusetts
|
-$501K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$289K |
| 4 |
Renaissance Technologies
New York
|
-$237K |
| 5 |
JG
Jefferies Group
New York
|
-$164K |
LCTX Hedge Fund Activity: Q1 2019 in Review
118 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2019, worth a combined $85.9M — up 65% from $52.1M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new LCTX positions and 17 closed out — a net gain of 13 holders — while 44 added to existing stakes and 20 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $4.67M. The largest seller was IndexIQ Advisors, exiting entirely with an estimated $715K sold.
- 118 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2019, up from 105 in Q4 2018.
- Funds reported $85.9M of Lineage Cell Therapeutics stock for Q1 2019, up 65% quarter-over-quarter.
- 30 funds opened new Lineage Cell Therapeutics positions in Q1 2019 and 17 closed out, a net change of +13 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2019 was Broadwood Capital, an estimated $4.67M added.
- The largest Lineage Cell Therapeutics seller in Q1 2019 was IndexIQ Advisors, an estimated $715K sold.
Based on aggregated 13F filings for Q1 2019.